会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 64. 发明公开
    • 글루탐산을 생산하는 코리네형 세균을 이용한 폴리감마 글루탐산의 제조방법
    • 使用生产CORYNE-BACTERIA的谷氨酸生产聚谷氨酸的方法
    • KR1020050025824A
    • 2005-03-14
    • KR1020030062761
    • 2003-09-08
    • 주식회사 바이오리더스
    • 성문희박청김광석박제현최윤호김형범홍승표이일한정창민
    • C12N1/21
    • C12N15/74C12P13/14C12R1/15
    • A method for producing poly-gamma-glutamate using a glutamate producing Coryne-type microorganism is provided, thereby reducing the production costs by adding no glutamate into a medium, producing large molecular weight of poly-gamma-glutamate by using Coryne-type microorganism having no enzyme decomposing poly-gamma-glutamate, and easily recovering poly-gamma-glutamate from the cultured Coryne-type microorganism that is easily recovered from the medium. A transformed Coryne-type microorganism with a vector pEC99-HCE-pgsBCA comprising genes encoding enzymes producing poly-gamma-glutamate is provided, wherein the gene encoding the enzyme producing poly-gamma-glutamate is isolated from Bacillus subtilis chungkookjang(KTCC 0697BP); and the genes encoding the enzymes producing poly-gamma-glutamate are pgsB, pgsC and pgsA; the Coryne-type microorganism is Corynebacterium sp. or Brevibacterium sp.; and the Corynebacterium sp. is Corynebacterium glutamicum(ATCC 13032). The method for producing poly-gamma-glutamate comprises culturing a glutamate producing Coryne-type microorganism in a medium without glutamate.
    • 提供了使用谷氨酸生产棒状微生物生产聚-γ-谷氨酸的方法,由此通过在培养基中不添加谷氨酸来降低生产成本,通过使用具有谷氨酸的棒状微生物产生大分子量的聚-γ-谷氨酸 没有酶分解聚-γ-谷氨酸盐,并且容易地从容易从培养基中回收的培养的棒状细菌中回收聚-γ-谷氨酸。 提供了包含编码产生多聚-γ-谷氨酸的酶的基因的载体pEC99-HCE-pgsBCA的转化棒状型微生物,其中编码产生多聚谷氨酸的酶的基因从枯草芽孢杆菌chungkookjang(KTCC 0697BP)分离; 并且编码产生多聚-γ-谷氨酸的酶的基因是pgsB,pgsC和pgsA; 棒状微生物是棒状杆菌属。 或短杆菌属。 和棒状杆菌属 是谷氨酸棒杆菌(ATCC 13032)。 制备聚-γ-谷氨酸的方法包括在不含谷氨酸的培养基中培养产生谷氨酸的棒状细菌。
    • 66. 发明公开
    • 바실러스 속 균주 유래의 폴리 감마 글루탐산합성유전자를 이용한 펩타이드 항생물질 P5와Anal3의 표면 발현 방법 및 그의 용도
    • 使用PGS BCA基因的表达P5和ANAL3表达的方法
    • KR1020040034780A
    • 2004-04-29
    • KR1020020063379
    • 2002-10-17
    • 한국생명공학연구원주식회사 바이오리더스학교법인조선대학교
    • 성문희홍승표이종수정창민함경수이동건박윤경김철중부하령
    • C12N15/63
    • C12N15/70A61K35/747C12N15/746C12Y603/02
    • PURPOSE: A method for surface expression of peptides P5 and Anal3 using pgs BCA gene is provided, thereby removing a purification process of peptides P5 and Anal3, and using useful lactic acid bacteria for the surface expression, so that peptide antibiotics can be cheaply and stably mass-produced. CONSTITUTION: A surface expression vector of antibiotics pHCE1LB:pgsA-P5 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide P5 encoded by the nucleotide sequence set forth in SEQ ID NO: 4. Transformed microorganisms with the vector pHCE1LB:pgsA-P5, Escherichia coli(KCTC 10350BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide P5 is surface expressed, or peptide P5 contained Lactobacillus floating matters as effective components. A surface expression vector of antibiotics pHCE1LB:pgsA-Anal3 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide Anal3 encoded by the nucleotide sequence set forth in SEQ ID NO: 6. Transformed microorganisms with the vector pHCE1LB:pgsA-Anal3, Escherichia coli(KCTC 10348BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide Anal3 is surface expressed, or peptide Anal3 contained Lactobacillus floating matters as effective components.
    • 目的:提供使用pgs BCA基因表达肽P5和Anal3的方法,从而消除肽P5和Anal3的纯化过程,并使用有用的乳酸菌进行表面表达,使肽抗生素可以廉价稳定 大规模生产的。 构成:抗生素pHCE1LB:pgsA-P5的表面表达载体包含一种或多种编码选自pgsB,pgsC和pgsA的聚氨基丁酸合酶复合物的基因,以及具有抗微生物,抗真菌和抗癌活性的基因偶极肽抗生素,其中偶极肽抗生素 与由SEQ ID NO:4所示的核苷酸序列编码的肽P5具有同源性。提供了具有载体pHCE1LB:pgsA-P5,大肠杆菌(KCTC 10350BP)或干酪乳杆菌的转化微生物。 用于抗微生物,抗真菌或抗癌的药物组合物包括其上表达肽P5的干酪乳杆菌,或肽P5含有乳杆菌漂浮物作为有效成分。 抗生素pHCE1LB:pgsA-Anal3的表面表达载体包含一个或多个编码选自pgsB,pgsC和pgsA的聚氨基丁酸合酶复合物的基因,以及具有抗微生物,抗真菌和抗癌活性的基因偶极肽抗生素,其中偶极肽抗生素具有同源性 与由SEQ ID NO:6所示的核苷酸序列编码的肽Anal3进行比较。提供了具有载体pHCE1LB:pgsA-Anal3,大肠杆菌(KCTC 10348BP)或干酪乳杆菌的转化微生物。 用于抗微生物,抗真菌或抗癌的药物组合物包括其上表达表达肽Anal3的干酪乳杆菌,或肽Anal3含有乳杆菌漂浮物作为有效成分。